---
aliases: [JPM 2026, JP Morgan Healthcare 2026, JPMorgan Healthcare Conference]
---
#event #healthcare #biopharma #conference

**JPM Healthcare Conference 2026** — 44th annual. Jan 12-15, San Francisco. 8,000+ attendees. Biggest healthcare investor event.

---

## Event details

| Metric | Value |
|--------|-------|
| Dates | **January 12-15, 2026** |
| Location | Westin St. Francis, San Francisco |
| Attendees | 8,000+ |
| Edition | 44th annual |
| Access | Invite-only (JPMorgan clients) |

---

## Key themes (2026)

| Theme | Focus |
|-------|-------|
| **M&A** | Multi-billion-dollar deals |
| **GLP-1** | Obesity drug competition |
| **AI drug discovery** | Platform deals, partnerships |
| **Oncology** | Immunotherapy, ADCs |
| **Patent cliffs** | 2028 Keytruda, Opdivo |
| **Biosimilars** | Market dynamics |

---

## Major presentations

### Day 1 — Monday, Jan 12

| Company | Time (PT) | Focus |
|---------|-----------|-------|
| [[Pfizer]] | Morning | CEO Bourla webcast |
| [[Tempus]] | 1:30-2:10 PM | AI diagnostics |
| Kardigan | 8:00 AM | Cardio pipeline, $554M raised |
| Exelixis | 5:15 PM | Oncology overview |
| Astellas | 3:00 PM | Pipeline update |

### Day 2 — Tuesday, Jan 13

| Company | Time (PT) | Focus |
|---------|-----------|-------|
| Celltrion | 3:45 PM | Biosimilars, novel drugs |
| Dentsply Sirona | 3:00 PM | Dental/medtech |

### Day 3 — Wednesday, Jan 14

| Company | Time (PT) | Focus |
|---------|-----------|-------|
| Emergent BioSolutions | 5:15 PM | CDMO, biodefense |
| Oculis | 1:30 PM | Ophthalmology pipeline |
| Vericel | 11:15 AM ET | Sports medicine |
| Aptar | 11:15 AM ET | Drug delivery |

---

## Expected announcements

| Company | Expected topic |
|---------|----------------|
| [[Johnson & Johnson]] | M&A plans for 2026 |
| [[Pfizer]] | Pipeline priorities, cost cuts |
| [[AbbVie]] | Skyrizi/Rinvoq guidance |
| [[Amgen]] | MariTide Phase 3 update |
| [[Novo Nordisk]] | Oral Wegovy launch plans |
| [[Eli Lilly]] | GLP-1 supply, pipeline |

---

## Deal-making context

**Why JPM matters for deals:**
- Sets M&A tone for the year
- Companies announce partnerships
- Licensing agreements revealed
- Pipeline collaborations

**2025 JPM highlights (reference):**
- AbbVie: Skyrizi/Rinvoq replacing Humira
- Amgen: MariTide obesity strategy
- Multiple AI drug discovery deals

---

## Satellite events

| Event | Host |
|-------|------|
| Biotech Showcase | EBD Group |
| RESI Conference | Life Science Nation |
| Capgemini Detox Breakfast | Capgemini |
| Merck Digital Science Studio | [[Merck]] |
| J&J Innovation 1:1s | [[Johnson & Johnson]] |
| CABS Investor Forum | CABS |

---

## What to watch

**GLP-1 updates:**
- Novo Nordisk oral Wegovy timeline
- Lilly supply expansion
- Amgen MariTide data

**M&A signals:**
- Patent cliff anxiety driving deals
- AI platform acquisitions
- China asset licensing

**Pipeline catalysts:**
- Phase 3 readouts
- FDA approval timelines
- New indication data

---

## Investment implications

| Signal | Meaning |
|--------|---------|
| Conservative guidance | Defensive positioning |
| M&A announcements | Pipeline gaps, urgency |
| AI partnerships | Technology validation |
| Supply commentary | Demand signals |

---

## Related

- [[Biopharma]] — sector
- [[Novo Nordisk]] — GLP-1 leader
- [[Eli Lilly]] — GLP-1 competitor
- [[Pfizer]] — presenting
- [[AbbVie]] — guidance watch
- [[CES 2026]] — same week tech event

---

## Sources

- [JPM Healthcare Conference](https://jpmannualhealthcareconference.com/)
- [BioSpace coverage](https://www.biospace.com/)
- [PharmExec previews](https://www.pharmexec.com/view/jp-morgan-2026-preview-johnson-johnson-fireside-chat)

*Created 2026-01-09*
